Skip to main
VCYT
VCYT logo

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 47%
Hold 7%
Sell 7%
Strong Sell 0%

Bulls say

Veracyte Inc. demonstrated strong growth in genomic testing volume, reaching 39,107 tests in 4Q24, which marked a 25% increase, notably driven by a record 22,400 urology tests from Decipher, reflecting a remarkable 45% increase. The company's testing revenue also showed robust performance, amounting to $112.2 million, up 24% compared to the previous quarter. Furthermore, the adjusted EBITDA margin improved significantly, rising by 690 basis points year-over-year, with management projecting continued growth to approximately 21.6% for 2025, indicating a positive trajectory for the company’s financial health.

Bears say

Veracyte Inc. is facing a negative outlook primarily due to slower-than-anticipated growth in its core testing offerings, particularly Afirma and Decipher, which may hinder overall revenue growth, projected at only 10-15%. Additionally, despite a decrease in SG&A and R&D expenses improving the non-GAAP operating margin, the decline in revenue per test from $2,894 to $2,868 indicates potential pricing pressure. Furthermore, headwinds related to a possible exit from the VCYT subsidiary may further dampen revenue expectations for 2025, raising concerns about the company’s ability to maintain its strategic focus and execution effectiveness.

Veracyte (VCYT) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 47% recommend Buy, 7% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 15 analysts, Veracyte (VCYT) has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.